Rockefeller Capital Management
HBIO icon

Rockefeller Capital Management’s Harvard Bioscience HBIO Stock Holding History

Rockefeller Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$6K – 2657
2020
Q2 		$6K Hold
200
– – ﹤0.01% 2035
2020
Q1 		$4K Hold
200
– – ﹤0.01% 2018
2019
Q4 		$6K Buy
+200
New +$5.75K ﹤0.01% 1743

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Rockefeller Capital Management's HBIO Position: Q3 2020 in Review

Rockefeller Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2020, closing a stake of 200 shares — an estimated $6K sold.

Rockefeller Capital Management first reported a position in HBIO in Q4 2019 and held it in 3 quarters. The position peaked at $6K in Q2 2020. 85 funds tracked by Wall St. Rank hold HBIO as of Q3 2020.

  • Rockefeller Capital Management reported no remaining Harvard Bioscience position as of Q3 2020 after selling out during the quarter.
  • Rockefeller Capital Management sold 200 Harvard Bioscience shares in Q3 2020, an estimated $6K.
  • Rockefeller Capital Management first reported a position in Harvard Bioscience in Q4 2019 and held it in 3 quarters.
  • Rockefeller Capital Management's Harvard Bioscience position peaked at $6K in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2020.

Based on Rockefeller Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.